Real-World Effectiveness of Anti-IL-23 vs Anti-TNF Monoclonal Antibodies in IBD: A Propensity Score-Weighted Analysis (ACG 2026) - Aug 29, 2026 - Abstract #P1085; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "RIS = Risankizumab, GUS = guselkumab, UST = ustekinumab, CTZ = certolizumab, ADA = adalimumab, GOL = golimumab, IFX = infliximab and -BS = biosimilar. In 137 patients with UC and 260 with CD, there were significant baseline differences between the IL23A and TNFA groups (Fig 1). Over 90% of the estimated sample size in each cohort was retained after fitting propensity score weighted models. In patients with UC, IL23A was associated with increased odds of clinical response at all 3 timepoints and remission (notably post-induction, OR 1.93, p < 0.05) (Fig 2a)."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A
|
|
Varun Pai BA 1; Emely Fernandez BA 2; Will Simmons MPH 1; Laura Sahyoun MD MBS 2; Michael Mintz MD 3; Jennifer Claytor MD MS 4; Ellen J. Scherl MD 2; Randy S. Longman MD PhD 2; Dana J. Lukin MD PhD 2
|